Christina Gross, Ph.D., of Emory University, will conduct a pilot study to examine the mechanisms underlying brain dysfunction in ASD. Using a mouse model, she will test whether a drug can correct the production of ribosomal protein S6. Normalizing production of this protein may be a therapeutic target for treatment of fragile X syndrome and a subgroup of those with autism.
James Gusella, Ph.D., of Massachusetts General Hospital, will also study brain function by examining how clusters of autism-associated genetic mutations influence shared brain pathways. Prior research suggests that many autism-linked genes influence one or more shared brain pathways. If so, effective treatments could be targeted to these shared processes. Such an approach could deliver more effective and broad-based treatments than individualized, gene-targeted treatments.
Edward Quadros, Ph.D., of the State University of New York, Downstate Medical Center, will explore how folate influences fetal brain development and autism risk. He will also explore folinic acid administration as a possible treatment for individuals with ASD and cerebral folate deficiency.
GI disturbances associated with ASD will be explored by Brent Williams, Ph.D., of Columbia University, who wi
|Contact: Jane E. Rubinstein|